Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca: Aspirin May Be To Blame For Poor Results In Some Brilinta Trial Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Uncertainty over aspirin usage among a North American subgroup of trial patients continues to raise speculation about an FDA review.
Advertisement

Related Content

FDA Will Present Brilinta Panel With Alternative Explanation For Negative U.S. Data
FDA Will Present Brilinta Panel With Alternative Explanation For Negative U.S. Data
AstraZeneca's Brilinta: Can Advisory Committee Help Build Momentum?
AstraZeneca's Brilinta: Can Advisory Committee Help Build Momentum?
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts
Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts

Topics

Advertisement
UsernamePublicRestriction

Register

PS068675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel